{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nintedanib+%28BIBF1120%29", "query": { "intervention": "Nintedanib (BIBF1120)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nintedanib+%28BIBF1120%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T01:56:54.004Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02225405", "title": "Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage IB Non-Small Cell Lung Carcinoma AJCC v7", "Stage II Non-Small Cell Lung Cancer AJCC v7", "Stage IIA Non-Small Cell Lung Carcinoma AJCC v7", "Stage IIB Non-Small Cell Lung Carcinoma AJCC v7", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-04-03", "completion_date": "2024-05-06", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02225405" }, { "nct_id": "NCT02299141", "title": "Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Non-Small Cell Lung Cancer", "Nonsmall Cell Lung Cancer" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-05-07", "completion_date": "2025-04-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02299141" }, { "nct_id": "NCT05483907", "title": "To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "BBT-877", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bridge Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 129, "start_date": "2023-04-12", "completion_date": "2025-02-23", "has_results": false, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05483907" }, { "nct_id": "NCT05285982", "title": "A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Diseases, Interstitial" ], "interventions": [ { "name": "Nintedanib (Ofev®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 54, "start_date": "2022-04-06", "completion_date": "2025-08-13", "has_results": true, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05285982" }, { "nct_id": "NCT01015118", "title": "LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "BIBF 1120", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1366, "start_date": "2009-11-17", "completion_date": "2016-09-15", "has_results": true, "last_update_posted_date": "2017-12-07", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 33, "location_summary": "Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01015118" }, { "nct_id": "NCT04419506", "title": "A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "BI 1015550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 147, "start_date": "2020-07-28", "completion_date": "2021-10-15", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 11, "location_summary": "Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chesterfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419506" }, { "nct_id": "NCT02234596", "title": "Nintedanib in Patients With Advanced Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Adenocarcinoma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2014-09-04", "completion_date": "2020-04-22", "has_results": true, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234596" }, { "nct_id": "NCT06625489", "title": "A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Part A: Placebo", "type": "DRUG" }, { "name": "Nintedanib", "type": "DRUG" }, { "name": "GSK3915393", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 50, "start_date": "2024-10-07", "completion_date": "2024-11-25", "has_results": false, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 2, "location_summary": "Cypress, California • Las Vegas, Nevada", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625489" }, { "nct_id": "NCT03717012", "title": "Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Pulmonary rehabilitation program", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 19, "start_date": "2018-11-15", "completion_date": "2020-06-10", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Loma Linda, California • Danbury, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Danbury", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03717012" }, { "nct_id": "NCT02902484", "title": "Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer of Pancreas" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-09-07", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-10-06T01:56:54.004Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02902484" } ] }